EUVIMEDEUVIMED entdecken
KohortenstudieOpen Access · CC BY 4.0

Optimal Primary Prophylaxis for Febrile Neutropenia During Neoadjuvant Cisplatin and 5‐Fluorouracil Plus Docetaxel for Esophageal Cancer: A Retrospective Cohort Study

Ryosuke Kumanishi iD, Hiroya Taniguchi, Taiko Nakazawa, Takatsugu Ogata, Yuki Matsubara, Hiroyuki Kodama, Akinobu Nakata, Kazunori Honda, Toshiki Masuishi, Yukiya Narita, Shigenori Kadowaki iD, Masashi Ando und 3 weitere

Cancer Medicine · 2025

DOI: 10.1002/cam4.70889 ↗

Kurz gefasst

Kohortenstudie in der Zeitschrift Cancer Medicine, 2025. Verfasst von Ryosuke Kumanishi und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Oncology, Aichi Cancer Center Hospital, Nagoya, Japan. Hauptthemen laut MEDLINE: Esophageal Neoplasms, Antineoplastic Combined Chemotherapy Protocols, Febrile Neutropenia. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 28 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Neoadjuvant chemotherapy (NAC) with docetaxel, cisplatin, and 5‐fluorouracil (5‐FU) (DCF) is the standard treatment for locally advanced esophageal cancer (LAEC). DCF is associated with a high risk of febrile neutropenia (FN), but the optimal primary prophylaxis remains unclear. The present study aimed to assess risk factors for FN and efficacy of primary prophylaxis using granulocyte colony‐stimulating factor (G‐CSF) and antibiotics in LAEC patients treated with DCF.

Methods

Patients with LAEC who received DCF as NAC between January 2016 and June 2022 at Aichi Cancer Center Hospital were retrospectively analyzed. DCF consisted of docetaxel 70 mg/m 2 on day 1, cisplatin 70 mg/m 2 on day 1, and 5‐FU 750 mg/m 2 by continuous infusion over 5 days. The patients were divided into Cohort A [no G‐CSF], B1 (G‐CSF after day 6), and B2 (G‐CSFon day 3–4). The efficacy of primary prophylaxis with G‐CSF and antibiotics during the first cycle was evaluated. The potential FN risk factors were evaluated using univariate and multivariate analyses.

Results

Among the 156 patients with esophageal cancer who received DCF as NAC, 41 (26%) patients developed FN during the first cycle. Multivariate analysis revealed that prophylactic antibiotics (17% vs. 40%; adjusted OR, 0.34; 95% confidence interval [CI], 0.16–0.73; p = 0.006) and G‐CSF (6% vs. 35%; adjusted OR, 0.14; 95% CI, 0.04–0.47; p = 0.002) were associated with lower FN incidence. The grade 3/4 neutropenia rates were 84%, 43%, and 13% in cohorts A, B1, and B2, respectively. FN incidence was 35%, 13%, and 0% in the respective cohorts. Treatment‐related death occurred in 2% of patients, none of whom received G‐CSF prophylaxis.

Conclusions

Prophylactic G‐CSF and antibiotics reduce the risk of FN in patients with LAEC treated with DCF. Early timing of G‐CSF administration showed a potential trend toward reduced FN risk and may offer additional benefits; however, these findings must be validated.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Esophageal NeoplasmsAntineoplastic Combined Chemotherapy ProtocolsFebrile NeutropeniaHumansMaleFemaleFluorouracilDocetaxelRetrospective StudiesMiddle AgedCisplatinAgedNeoadjuvant TherapyGranulocyte Colony-Stimulating FactorRisk FactorsAnti-Bacterial AgentsAntibiotic ProphylaxisAdult

Stichwörter der Autor:innen

5‐fluorouracilcisplatindocetaxelesophageal cancerfebrile neutropenianeoadjuvant chemotherapy

Substanzen

FluorouracilDocetaxelCisplatinGranulocyte Colony-Stimulating FactorAnti-Bacterial Agents

Autor:innen und Institutionen

  • Department of Clinical Oncology, Aichi Cancer Center Hospital, Nagoya, Japan.
  • Department of Endoscopy, Aichi Cancer Center Hospital, Nagoya, Japan.
  • Department of Gastroenterological Surgery, Aichi Cancer Center Hospital, Nagoya, Japan.

ORCID-Profile: Ryosuke Kumanishi, Shigenori Kadowaki, Kei Muro

Zitieren

APA

Kumanishi, R., Taniguchi, H., Nakazawa, T., Ogata, T., Matsubara, Y., Kodama, H., Nakata, A., Honda, K., Masuishi, T., Narita, Y., Kadowaki, S., Ando, M., Tajika, M., Abe, T., & Muro, K. (2025). Optimal Primary Prophylaxis for Febrile Neutropenia During Neoadjuvant Cisplatin and 5‐Fluorouracil Plus Docetaxel for Esophageal Cancer: A Retrospective Cohort Study. Cancer Medicine. https://doi.org/10.1002/cam4.70889

Vancouver

Kumanishi R, Taniguchi H, Nakazawa T, Ogata T, Matsubara Y, Kodama H, et al. Optimal Primary Prophylaxis for Febrile Neutropenia During Neoadjuvant Cisplatin and 5‐Fluorouracil Plus Docetaxel for Esophageal Cancer: A Retrospective Cohort Study. Cancer Medicine. 2025. doi:10.1002/cam4.70889

BibTeX
@article{Kumanishi2025,
  author = {Kumanishi, Ryosuke and Taniguchi, Hiroya and Nakazawa, Taiko and Ogata, Takatsugu and Matsubara, Yuki and Kodama, Hiroyuki and Nakata, Akinobu and Honda, Kazunori and Masuishi, Toshiki and Narita, Yukiya and Kadowaki, Shigenori and Ando, Masashi and Tajika, Masahiro and Abe, Tetsuya and Muro, Kei},
  title = {Optimal Primary Prophylaxis for Febrile Neutropenia During Neoadjuvant Cisplatin and 5‐Fluorouracil Plus Docetaxel for Esophageal Cancer: A Retrospective Cohort Study},
  journal = {Cancer Medicine},
  year = {2025},
  doi = {10.1002/cam4.70889}
}
Kostenlos starten →